Prostate cancer screening may detect nonprogressive cancers, leading to overdiagnosis
and overtreatment. The potential for overdiagnosis can be assessed from the reservoir of …

Widespread prostate‐specific antigen (PSA) screening detects many cancers that would
have otherwise gone undiagnosed. To estimate the prevalence of unsuspected prostate …

Purpose To assess long-term outcomes of men with favorable-risk prostate cancer in a
prospective, active-surveillance program. Methods Curative intervention was recommended …

Subclinical prostate cancer is common in men> 50 years of age. Population-based
screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) …

Background The prostate-specific antigen (PSA) test is used to screen for prostate cancer
but has a high false-positive rate that translates into unnecessary prostate biopsies and …

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2] proPSA
into a single score. It was recently approved by the FDA and is now commercially available …

Abstract Purpose: Serum PSA (sPSA) testing has led to the identification of patients with
indolent prostate cancer, and inevitably overtreatment has become a concern. Progensa …

Statistical illiteracy can have an enormously negative impact on decision making. This
volume of collected papers brings together applied and theoretical research on risks and …

Background: Many men with elevated prostate-specific antigen (PSA) levels in serum do not
have aggressive prostate cancer and undergo unnecessary biopsy. Retrospective studies …

Background: New screening methods that can add predictive diagnostic value for
aggressive (high-grade, Gleason score⩾ 7) prostate cancer (PCa) are needed to reduce …